London. Europe’s Hub for Global Early-Phase Trials
Purpose-designed unit in north-west London, close to Central Middlesex Hospital, our facility specialises in early-phase trials requiring large-scale inpatient capacity, complex study designs, and integrated hospital-grade services.
A Centre of Excellence in Early-Phase Research Across the UK and Europe
With more than 30 years of continuous operation, our London site is the oldest and one of the most respected early-phase clinical pharmacology units in Europe. Since opening in 1993, we have delivered over 1,000 studies, from first-in-human trials to complex adaptive designs, for more than 100 sponsors worldwide ranging from emerging biotechs to leading global pharmaceutical companies.
34 percent of our sponsors return for additional studies, a testament to our scientific excellence, participant safety, and dependable delivery.
From London to the World: Part of the Only Unified, Global Early-Phase Network
Now part of the Nucleus Network unified, global network, HMR offers sponsors a 145-bed, purpose-built clinical pharmacology unit with integrated pharmacy, laboratory, outpatient clinic, and ward facilities. Harmonised processes, shared best practices, and coordinated project delivery across our UK, Australian, and US sites enable sponsors to start, expand, or run studies in parallel across three major regulatory regions with consistent quality and seamless execution.
Fast facts
145 across four floors, including outpatient and sleep units
Beds
Purpose-designed unit in north-west London, close to Central Middlesex Hospital
Co-Location
First-in-human (healthy volunteers and patients), Drug-drug interaction, Vaccine, Biosimilar, TQT (Thorough QT), Renal and hepatic impairment studies with on-site dialysis capability
Specialties
MHRA MIA(IMP)-licensed GMP pharmacy (including aseptic suites), ISO 17025-accredited lab with barcode sample tracking, radiopharmacy aseptic suite, automated handling, and secure storage with environmental monitoring
MHRA Phase I accreditation (including supplemental), MIA(IMP), Home Office licence for controlled drugs, ISO 9001, ISO 17025, ISO 27001, Environment Agency licence for radiolabelled trials
Certifications
One of Europe’s largest Phase I units with a diverse and inclusive volunteer and patient database, proven recruitment track record across healthy, elderly, and targeted patient cohorts
Participant Access
Why London?
- Strategic location in a global research hub with deep access to diverse and inclusive volunteer and patient populations
- Close proximity to NHS and emergency services for participant safety and rapid response
- Fully integrated “one roof” model with clinical project management, regulatory affairs, clinical science, data management, statistics, medical writing, quality, laboratory, pharmacy, and recruitment all co-located for speed and clear accountability
- Highly trained staff including a 24/7 resuscitation team, experienced physicians and scientists, and national awards for clinical excellence
- Part of the Nucleus Network unified, global network enabling trials to run in parallel across three continents with harmonised protocols and coordinated delivery
- Established regulatory expertise with more than 1,000 MHRA submissions and strong relationships with regulators and ethics committees
Specialist Capabilities for Complex Early-Phase Trials
- First-in-human (healthy volunteers and patients)
- Drug-drug interaction
- Vaccine
- Biosimilar
- TQT (Thorough QT)
- Renal and hepatic impairment studies, including on-site dialysis
- Vaccines and biologics, including infectious disease studies
- PET and fMRI imaging
- Metabolic and endocrine, including diabetes and obesity
- Respiratory and cardiovascular studies
- CNS and psychiatric indications, including psychedelic compounds
- Healthy volunteer studies and targeted patient cohorts
- Cardiology, including QT/QTc assessments
What Sponsors Can Expect at Our London Site
- Large-scale screening and dosing capacity within a 145-bed, purpose-built facility
- Adaptive, multi-part protocols that allow changes to dosing, procedures, and endpoints within weeks without resubmission delays
- Proven recruitment strength supported by one of Europe’s largest and most inclusive volunteer and patient databases
- Access to local NHS specialists for protocol-specific assessments
- 24/7 medical coverage with on-site resuscitation and rapid hospital transfer protocols
- MHRA Phase I accredited with processes aligned to FDA, EMA, and ICH GCP standards
Partner With Us
Whether you are planning a first-in-human trial, a complex adaptive design, or a specialist patient cohort study, our London facility delivers the expertise, infrastructure, and speed you need.
Contact us today to discuss your study requirements and experience the benefits of working with the Nucleus Network unified, global early-phase network.
